News

A University of Colorado professor has won the 2024 Alton Ochsner Award Relating Smoking and Disease for his work into how genetic and environmental factors, including smoking, contribute to a person’s risk of idiopathic pulmonary fibrosis (IPF) — when the disease is due to unknown causes. The $15,000 prize…

Avalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF). The MIST trial (NCT06329401) is expected to enroll 300 progressive PF patients, who will receive either one of…

Researchers have identified immune cell populations that could be used to help distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis (IPF), a study suggests. People with hypersensitivity pneumonitis, which is a rare type of pulmonary fibrosis (PF), show elevated levels of certain types of immune cells in the…

This September, supporters will participate in advocacy, educational, and fundraising activities intended to raise awareness about pulmonary fibrosis (PF) and interstitial lung diseases (ILDs) in honor of PF Awareness Month. As it does each year, the Pulmonary Fibrosis Foundation (PFF) will play a central role in the…

Avalyn Pharma has initiated a Phase 1b clinical trial to test AP02, a therapeutic candidate for pulmonary fibrosis (PF), in adult healthy volunteers. The placebo-controlled trial of inhaled nintedanib will assess its safety, tolerability, and pharmacological profile when given at single or multiple ascending doses. Its main goal…

Reviva Pharmaceuticals has been awarded a U.S. patent covering the use of its experimental therapy brilaroxazine in treating people with pulmonary fibrosis. The patent, No. 12053477, granted by the U.S. Patent and Trademark Office specifically covers the use of brilaroxazine in idiopathic pulmonary fibrosis (IPF), as well…

Brainomix, a U.K.-based software company, has joined forces with Boehringer Ingelheim, a German pharmaceutical company, to accelerate the diagnosis of pulmonary fibrosis (PF) in the U.S. and improve treatment access for people with scarring of the lungs. As part of the collaboration, Brainomix’s artificial intelligence (AI)-powered tool, called Brainomix 360…

Enrollment has been completed for a Phase 2a study that’s testing idiopathic pulmonary fibrosis (IPF) treatment BBT-877, an investigational therapy from Bridge Biotherapeutics. The Phase 2a trial (NCT05483907) is evaluating the safety, tolerability, and efficacy of BBT-877 in 120 adults with IPF, ages 40 and older, with or…

Enrollment is complete for a Phase 3 clinical trial testing Tyvaso (treprostinil) inhalation solution for idiopathic pulmonary fibrosis (IPF), United Therapeutics, the therapy’s developer, said. The TETON 2 study (NCT05255991) will evaluate the treatment’s safety and efficacy in 597 adults with IPF, 40 years and older,…

An interdisciplinary group of researchers at the University of Wisconsin (UW)-Madison have received nearly $11 million to study the biological processes that promote lung scarring in idiopathic pulmonary fibrosis (IPF). Funding comes from a four-year grant (HT94252410543) provided by the U.S. Department of Defense. The research will be…